Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 777,332 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 777,332 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $23.07, for a total value of $17,933,049.24. Following the transaction, the director directly owned 16,353,113 shares in the company, valued at approximately $377,266,316.91. This represents a 4.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00.

Roivant Sciences Stock Down 4.0%

ROIV stock opened at $21.79 on Friday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $23.47. The firm has a market cap of $15.15 billion, a price-to-earnings ratio of -38.91 and a beta of 1.22. The business’s fifty day simple moving average is $19.88 and its two-hundred day simple moving average is $14.99.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently added to or reduced their stakes in ROIV. Amundi grew its position in Roivant Sciences by 18.1% during the 1st quarter. Amundi now owns 398,729 shares of the company’s stock worth $3,991,000 after purchasing an additional 61,214 shares during the last quarter. Inspire Investing LLC acquired a new stake in shares of Roivant Sciences during the first quarter worth $303,000. IFG Advisory LLC purchased a new stake in shares of Roivant Sciences during the second quarter valued at $255,000. Valeo Financial Advisors LLC acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at $1,145,000. Finally, Franklin Resources Inc. purchased a new position in Roivant Sciences in the 2nd quarter worth $997,000. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of several research reports. Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday. Bank of America raised their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a report on Thursday, September 18th. Jefferies Financial Group upped their target price on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings raised Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Finally, Leerink Partners lifted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.